UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013098
Receipt number R000015275
Scientific Title A phase II trial of uracil ointment for the prevention of capecitabine induced hand-foot syndrome (HFS): .
Date of disclosure of the study information 2014/02/14
Last modified on 2023/02/13 11:34:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase II trial of uracil ointment for the prevention of capecitabine induced hand-foot syndrome (HFS): .

Acronym

P2 trial of uracil ointment

Scientific Title

A phase II trial of uracil ointment for the prevention of capecitabine induced hand-foot syndrome (HFS): .

Scientific Title:Acronym

P2 trial of uracil ointment

Region

Japan


Condition

Condition

Advanced or recurrent breast cancer

Classification by specialty

Breast surgery Dermatology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Aim of this trial is to evaluate the prophylactic efficacy of uracil ointment for capecitabine induced hand-foot syndrome in advanced or recurrent breast cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Incidence and appearance time of Grade 2 HFS.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Uracil ointment application to the palmar and plantar skin.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Histologically confirmed advanced or recurrent breast cancer.

Key exclusion criteria

Had previous treatment with capecitabine.

Target sample size

35


Research contact person

Name of lead principal investigator

1st name Tetsuya
Middle name
Last name Taguchi

Organization

Kyoto Prefectural University of medicine

Division name

Department of Endocrine & Breast Surgery

Zip code

6020841

Address

465 Kajii-cho Kawaramachi Hirokoji Kamigyo-ku Kyoto Japan

TEL

0752515534

Email

ttaguchi@koto.kpu-m.ac.jp


Public contact

Name of contact person

1st name Tetsuya
Middle name
Last name Taguchi

Organization

Kyoto Prefectural University of medicine

Division name

Department of Endocrine & Breast Surgery

Zip code

602-8566

Address

465 Kajii-cho Kawaramachi Hirokoji Kamigyo-ku Kyoto Japan

TEL

075-251-5534

Homepage URL


Email

breast@koto.kpu-m.ac.jp


Sponsor or person

Institute

Kyoto Prefectural University of medicine

Institute

Department

Personal name

Tetsuya Taguchi


Funding Source

Organization

Grants-in-Aid for Scientific Research

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Ethics Reviewer Board, Kyoto Prefectural University of Medicine

Address

465 Kajii-cho Kawaramachi Hirokoji Kamigyo-ku Kyoto Japan

Tel

0752515337

Email

rinri@koto.kpu-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

京都府立医科大学附属病院(京都府)


Other administrative information

Date of disclosure of the study information

2014 Year 02 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 07 Month 14 Day

Date of IRB

2012 Year 07 Month 25 Day

Anticipated trial start date

2012 Year 10 Month 01 Day

Last follow-up date

2014 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2016 Year 06 Month 30 Day


Other

Other related information



Management information

Registered date

2014 Year 02 Month 06 Day

Last modified on

2023 Year 02 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015275


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name